Further, it was found that the survival rate of patients with PAAD with TP53 mutation decreased rapidly to 50% within one and a half years of onset, whereas the survival rate of patients with PAAD with TP53 wild/GS-like remained above 50% after 4 years of onset. This evidence concerns the gene TP53 and pancreatic adenocarcinoma.